Sponsors (5)
The bill speeds federal ability to identify and control emerging dangerous imported synthetics and increases criminal penalties and procedural clarity—trading quicker public-health protections and enforcement for broader executive scheduling power that may hasten criminalization, restrict research/medical access, deepen sentencing disparities, and raise compliance costs for businesses.
People threatened by rapidly emerging synthetic or imported psychoactive drugs will see faster federal controls that can reduce the spread and availability of dangerous new substances.
Victims of trafficking and serious harm from Schedule A substances (and the public) gain stronger criminal penalties and accountability for traffickers, potentially deterring distribution and increasing victim justice.
Researchers, regulated importers/exporters, state agencies, and health systems get clearer procedures and deadlines for temporary and permanent scheduling, plus expedited administrative hearings, improving regulatory predictability.
People who possess, sell, or research novel imported compounds face faster criminalization because temporary scheduling can be imposed based on predicted effects or structural similarity rather than demonstrated harm.
Temporary emergency scheduling powers without immediate judicial review can restrict access to substances for medical research, clinical use, and legitimate industrial purposes, with limited legal recourse while restrictions remain in place.
Mandatory long prison terms, bans on probation for injury/death cases, and higher fines remove judicial discretion and risk disproportionately harsh outcomes and widened racial disparities in enforcement.
Based on analysis of 16 sections of legislative text.
Introduced November 20, 2025 by Charles Ernest Grassley · Last progress November 20, 2025
Creates a new federal "Schedule A" for certain imported or import-offered drugs that are chemically similar to controlled substances and have comparable or greater stimulant, depressant, or hallucinogenic effects. The Attorney General would gain authority to temporarily place such substances into Schedule A (with set notice and time limits) and later make permanent scheduling decisions; HHS scientific review can block permanent scheduling. The bill raises criminal penalties for importing or exporting Schedule A substances, requires specific IUPAC labeling for imported/exported Schedule A products (with narrow FDA exceptions), sets rules for research registrations and expedited review, and lets people convicted under Schedule A rules seek sentence reductions if the substance is later decontrolled or moved to a lower schedule.